

Serotonin Syndrome After Methylene Blue Administration: A Case Report



Tiffany Cung, MS4; Sarah Perman, MD

DEFINITION

- Toxidrome due to excessive serotonin receptor activities in central nervous system
- Normally due to medications and drug interactions
- Several drug classes have serotonergic effects
- Wide range of clinical presentation
- Life-threatening
 - Mortality around 11%

EPIDEMIOLOGY

- First noted in 1960s in studies of single and combination antidepressants usage
- All age groups involved
- Incidence of syndrome parallels with increased use of serotonergic agents
- Most likely drug class associated with syndrome: serotonin reuptake inhibitors
- Might be more common among chronically and/or critically ill patients due to multiple drug use and decreased drug metabolism
- Incidence difficult to assess due to misdiagnosis and dismissal of mild symptoms

MechanismsExamplesDecrease serotonin reuptakeSSRI, tricyclic antidepressants, tramadol, buprenorphine, carbamazepine, valproate, ondansetron, metoclopramide, St. John's wortDecrease serotonin breakdownMAOI, linezolid, methylene blueIncrease serotonin precursors/ formationTryptophanIncrease serotonin releaseCocaine, fentanyl, amphetamines,

methylenedioxymethamphetamine

Erythromycin, ciprofloxacin, fluconazole,

COMMON CAUSES

CLINICAL PRESENTATION

grapefruit juice

- Neuromuscular excitation: myoclonus, hyperreflexia, akathisia, muscle rigidity, Babinski
- Autonomic dysfunction: diaphoresis, hypertension/hypotension, hyperthermia, mydriasis, diarrhea, nausea and vomiting, flushing, tachycardia
- Altered mental status


CYP2D6 and CYP2A4 inhibitors

CASE PRESENTATION

- 62-year-old male with history of ischemic cardiomyopathy status post left ventricular
 assist device (LVAD), prostate cancer, transient ischemic attack, type 2 diabetes mellitus,
 hypertension, obesity, obstructive sleep apnea, chronic obstructive pulmonary disease,
 chronic kidney disease, general anxiety disorder and depression
- Presented to emergency department for low flow alarms from LVAD
- Admitted to advanced heart failure service
- Approved for heart transplant and removal of LVAD
- Vasoplegia during surgery requiring methylene blue for vasopressor
- After surgery, worsening kidney function with creatinine level to 2.1 mg/dL from baseline of 1.6-1.8 mg/dL
- On post-op day 1, patient have difficulty following commands
 - Shaking or dorsiflexion of ankles and feet
 - Fever at max temperature of 38.7 degree Celsius
 - Tachycardic at 100 bpm
- **Differential diagnoses** for symptoms include infection, seizure, anticholinergic toxicity, neuroleptic malignant syndrome, serotonin syndrome
- Neurology consultation: determined likely serotonin syndrome
 - Patient had mildly dilated pupils, severe hypertonia of all extremities, lower extremity clonus, increased patellar reflex, rigid dorsiflexion of calcaneal tendon, Babinski's sign, roving extraocular movements
 - Patient takes bupropion XL 150 mg and sertraline 50 mg daily
 - Recommended midazolam with bolus of 2 mg IV then infusion
- Toxicology consultation: agreed with likely serotonin syndrome
 - Midazolam titrated up to 8 mg/hr for symptom control
 - Cooling blanket for elevated temperatures
- Symptom resolution on post-op day 2
 - Improved creatinine level and urine output

DIAGNOSIS

- Physical and neurological exam
- Patient's medication history
- Hunter Serotonin Toxicity Criteria considered as gold standard
 - Improved sensitivity and specificity to 84% and 97%, respectively
 - Systematic review of 412 cases showed that Hunter criteria miss 37% of cases while other criteria miss only 10 or 24% of cases



TREATMENT

- Symptomatic treatment
- Discontinue all serotonergic agents
- Cooling methods for hyperthermia and IV fluids for tachycardia and hypertension/hypotension
- No use for antipyretic medications
- Benzodiazepines for agitation
- Medications preferred over physical restraints to avoid risk of rhabdomyolysis and worsening hyperthermia
- Hyperthermia above 41°C should be intubated and paralyzed to address muscle rigidity
- Mild cases may just need close observation
- Can consider cyproheptadine if refractory

REFERFENCES

Boyer, E.W. (2022). Serotonin syndrome (serotonin toxicity). In Traub, S.J, Ganetsky, M. (Eds.), *Uptodate*. Available from <a href="https://www.uptodate.com/contents/serotonin-syndrome-serotonin-syndrom

toxicity: Search—serotonini / 20syndronie a source—search Tesuita serected inte—1 120 a disage type—default a display Tank—1#n10

Spadard, A., Scott, K. K., Royillan, A., & Long, B. (2022). High risk and low prevalence diseases. Serotonin syndrome. The American Journal of Emergency Medicine, 01, 50–57. https://doi.org/10.1010/j.ajem.2022

wang, K.Z., Vashistna, V., Kaur, S., Houchens, N.W. (2016). Serotonin Syndrome. Preventing, recognizing, and treating it. Cieveiana Chinic Journal of Medicine, 85 (11) 810-816 **Doi:** 10.5949/ccjiii.85a.15129

Poison Centers: 39th Annual Report. *Clinical toxicology (Philadelphia, Pa.), 60*(12), 1381–1643. https://doi.org/10.1080/15563650.2022.2132768

Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. *The New England journal of medicine*, 352(11), 1112–1120. https://doi.org/10.1056/NEJMra041867

Bartlett D. (2017). Drug-Induced Serotonin Syndrome. Critical care nurse, 37(1), 49–54. https://doi.org/10.4037/ccn2017169

Methylene blue and the risk of serotonin toxicity. Anesthesia Patient Safety Foundation. (2021, October 1). Retrieved January 17, 2023, from https://www.apsf.org/article/methylene-blue-and-the-risk-of-serotonin-toxicity/

Huang, W. H., & Li, M. J. (2022). Postoperative Serotonin Syndrome Following Administration of Preoperative Intrapulmonary Methylene Blue and Intraoperative Granisetron: A Case Report. The American Journal of Case Reports